Compare · JNJ vs ROIV
JNJ vs ROIV
Side-by-side comparison of Johnson & Johnson (JNJ) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $560.33B, about 27.3x ROIV ($20.56B).
- Over the past year, JNJ is up 49.9% and ROIV is up 158.1% - ROIV leads by 108.2 points.
- JNJ has been more active in the news (7 items in the past 4 weeks vs 6 for ROIV).
- JNJ has more recent analyst coverage (25 ratings vs 18 for ROIV).
- Company
- Johnson & Johnson
- Roivant Sciences Ltd.
- Price
- $232.71+1.95%
- $28.57-3.20%
- Market cap
- $560.33B
- $20.56B
- 1M return
- +3.67%
- -0.82%
- 1Y return
- +49.92%
- +158.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 6
- Recent ratings
- 25
- 18
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest JNJ
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
Latest ROIV
- President & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85, sold $6,054,000 worth of shares (200,000 units at $30.27) and covered exercise/tax liability with 34,483 shares, decreasing direct ownership by 2% to 1,613,063 units (SEC Form 4) (withholding obligation)
- CFO Pulik Richard covered exercise/tax liability with 18,962 shares, decreasing direct ownership by 6% to 278,549 units (SEC Form 4) to satisfy withholding tax
- SEC Form S-8 filed by Roivant Sciences Ltd.
- SEC Form 10-K filed by Roivant Sciences Ltd.
- Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
- Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.